Bugworks Research has pulled in more than $42 million in equity since 2018 to build a new class of antibiotic — and in the middle of the one clinical trial that mattered most, doctors in Adelaide found a blood clot at the infusion site of a healthy volunteer’s arm. That is the contradiction sitting at the heart of this Bengaluru biotech: a company trying to invent the kind of broad-spectrum antibiotic the world has not seen in decades, discovering along the way that the human body does not care how elegant the chemistry is.
The molecule is called BWC0977. It is designed to kill bacteria that current antibiotics cannot touch — carbapenem-resistant Acinetobacter baumannii, Klebsiella pneumoniae, Pseudomonas aeruginosa, the pathogens the World Health Organization lists as critical priorities. Bugworks Research, founded in 2014 by four scientists who lost their jobs when AstraZeneca shut its Bengaluru infectious-disease unit, has spent twelve years and four funding rounds trying to get that molecule through human trials. It has cleared a first-in-human study, drawn a global non-profit into a co-development deal covering 146 countries, and hit a safety scare serious enough to need its own dedicated cardiac sub-study. None of that shows up as revenue in the way a consumer startup’s does — which is exactly the point of this piece.
Quick facts
| Company | Bugworks Research (Bugworks Research India Private Limited, Bengaluru; and Bugworks Research Inc., Delaware, US) |
| Founded | 4 February 2014, incorporated in Bengaluru (Registrar of Companies filing via Tofler) |
| Founder(s) | Anand Anandkumar, Santanu Datta, V. Balasubramanian, Shahul Hameed |
| Businesses | Antibacterial drug discovery (lead candidate BWC0977) and an early immuno-oncology programme, both developed from Bengaluru |
| Latest FY revenue | ₹27.8 crore (about $2.9 million at $1 ≈ ₹96.0) in FY23 (year ended 31 March 2023), up 39.8% from FY22’s ₹19.9 crore, as per Tofler’s RoC-filing-based data |
| Latest FY profit/loss | A loss in FY23 (negative net margin), per Tofler; the company does not publicly disclose the absolute rupee figure, and no FY24 or FY25 filing summary is publicly available yet |
| Listed | Private — no IPO |
| Market value / last valuation | Not publicly disclosed as of September 2026; over $42.9 million raised in equity across rounds since 2018, per Tracxn and Inc42 company profiles |
| Key shareholders / CEO | Anand Anandkumar (CEO and MD); investors include Lightrock India, University of Tokyo Edge Capital, Global Brain Corporation, 3one4 Capital and Biocon’s Kiran Mazumdar-Shaw |
What they do
Bugworks Research designs small-molecule antibiotics meant to kill bacteria that no longer respond to the drugs hospitals already have, and, alongside that, an early-stage immuno-oncology programme aimed at solid tumours. Its lead asset, BWC0977, is a novel bacterial topoisomerase inhibitor built to attack two essential bacterial enzymes at once while dodging the efflux pumps that bacteria use to pump ordinary antibiotics back out of their cells — a mechanism the company calls its ELUDE platform. The customer, in the near term, is not a patient with a prescription card but the global health system itself: hospitals treating drug-resistant infections, health ministries stockpiling last-resort drugs, and non-profits such as the Global Antibiotic Research and Development Partnership (GARDP) that fund and distribute antibiotics in countries where the market alone will not pay for new ones. The company’s own account, on its website, is that BWC0977 targets pathogens on the World Health Organization’s critical- and high-priority lists, including carbapenem-resistant Acinetobacter baumannii, Klebsiella pneumoniae and Pseudomonas aeruginosa.
The origin
The founding insight did not come from a garage or a hackathon. It came from a shutdown. Anand Anandkumar spent close to two decades in the semiconductor industry before a personal health scare pushed him toward life sciences; in 2007 he co-founded Cellworks, a computational-biology company modelling cancer drugs, running teams in the Bay Area and Bengaluru. Cellworks later partnered with AstraZeneca’s Bengaluru infectious-disease research centre, Avishkar, to hunt for new tuberculosis drugs, and that is where Anandkumar met the scientists who would become his co-founders: Santanu Datta, V. Balasubramanian and Shahul Hameed, all senior researchers at Avishkar, a unit that at its peak employed some 300 people, per Forbes India’s June 2022 account of the company.
In 2014, AstraZeneca decided to shut Avishkar down entirely. Rather than scatter into other jobs, the four scientists decided the shutdown was the opening: if a major pharmaceutical company would not fund infectious-disease research in India, they would build a company that did. “Nobody’s going to fix problems in markets like India,” Anandkumar told Forbes India. “So we are getting an opportunity to do it ourselves.” Bugworks Research was incorporated within the year, built on the idea that the world’s arsenal against drug-resistant bacteria — untouched by a genuinely new class of antibiotic for decades — was the exact kind of hard, unfashionable science a big pharma company would abandon but a founder-led one might not.
The struggle years
The first struggle was structural, not scientific: getting anyone to pay for antibiotic research at all. Antibiotics are used for days, not years, priced low because health systems ration their use to slow resistance, and generic within a decade of launch — which is precisely why big pharmaceutical companies had been exiting the category, AstraZeneca’s own Avishkar closure among them. Bugworks had to build a business model almost entirely on grants and mission-driven capital rather than the promise of blockbuster sales, and it shows in where the money came from: CARB-X, the global non-profit accelerator for antibacterial research, is listed as a lead grant funder from the company’s earliest years, and Japanese investors such as the University of Tokyo Edge Capital (UTEC) and Global Brain Corporation, rather than Indian ones, wrote the first big equity cheques in 2018 and 2020.
The second struggle was clinical, and came later, once the science had actually made it into humans. Bugworks pushed BWC0977 into its first-in-human Phase 1 study on 8 November 2021 in Adelaide, Australia — a milestone the company’s own news page describes as the trial of “the first novel broad spectrum [antibiotic] in decades.” But getting a molecule into people is not the same as getting it through safely. By June 2022, GARDP was funding a dedicated cardiac-safety sub-study embedded inside that same Phase 1 programme, built specifically to assess whether the compound carried a risk of triggering an irregular heartbeat, as GARDP’s own announcement of the support states. Then, in its more recent reporting on the company, Forbes India (March 2025) recorded a second, separate scare: blood clotting was observed at the infusion site in two healthy volunteers during the intravenous arm of the Phase 1 trial, on top of the heart-rhythm testing already under way. Both are the kind of finding that can end a drug candidate outright; Bugworks instead had to slow down, investigate, and keep going.
The turning point
The clearest before-and-after moment is that November 2021 trial start. Before it, BWC0977 was a laboratory story: a molecule screened, according to Forbes India’s June 2022 profile, against some 10,000 bacterial isolates worldwide, backed by preclinical data and a compelling mechanism, but with zero human safety evidence — the stage at which most novel antibiotic programmes quietly die for lack of funding to cross into the clinic. After it, Bugworks had something almost no small Indian biotech has: a molecule actually dosed in people, first in single ascending doses and then multiple ascending doses, generating real pharmacokinetic and safety data rather than modelled projections. That data, however imperfect — it is what surfaced the cardiac-safety questions and the clotting event — is what let the company walk into its next negotiation from a position of substance rather than promise. It is also almost certainly what persuaded GARDP, a body that only backs products it believes can reach patients, to sign on as a development partner within three years of that first dose.
The money behind it
- Series A, $9 million — announced 14 August 2018, led by the University of Tokyo Edge Capital (UTEC), with 3one4 Capital, Acquipharma Holdings and existing angel investors participating; UTEC’s Atsushi Usami joined the board (PR Newswire, August 2018).
- Series B, $7.5 million — announced 23 April 2020, led by UTEC and Global Brain Corporation, with Acquipharma Holdings and 3one4 Capital returning; earmarked to complete the first phase of clinical research on the IV candidate (Inc42, April 2020).
- Series B1, $18 million — announced 9 February 2022, led by Lightrock India, with 3one4 Capital, UTEC, Global Brain, Acquipharma Holdings, I.M Holdings, Featherlite Group India and Biocon’s Kiran Mazumdar-Shaw in the syndicate; earmarked for clinical development of BWC0977 in both IV and oral forms and for the pre-clinical immuno-oncology asset (Inc42, February 2022).
- Total raised — more than $42.9 million in equity across rounds since 2018, per company profiles on Tracxn and Inc42 (accessed September 2026); a formal Series C had not been announced as of that date.
- CARB-X grant funding — CARB-X, the global non-profit accelerator, committed up to $6.2 million toward the Series A-era programme (PR Newswire, August 2018); Forbes India’s March 2025 reporting puts Bugworks’ cumulative non-dilutive grant funding, “primarily from CARB-X,” at roughly $8 million by that point.
- GARDP partnership — a co-development agreement signed in 2024 and expanded in July 2025 to cover an oral formulation; GARDP is providing technical and financial support through Phase 1 and, in return, holds manufacturing and commercialisation rights to BWC0977 in 146 countries, almost all of them low- and middle-income markets, if the drug is approved (GARDP’s official BWC0977 portfolio page, and CIDRAP, June 2024). Bugworks would retain rights in the US, EU, Japan and other high-income markets.
- What each backer changed — UTEC brought the introduction to Japanese microbiologist Professor Murakami that shaped the drug-design approach, per Forbes India’s June 2022 account; CARB-X and GARDP effectively substitute for the venture and pharma-partner money a typical biotech would raise, since antibiotics rarely attract it; and Kiran Mazumdar-Shaw’s participation lent the kind of India-biotech credibility a Bengaluru company needs when most of its cheques are being written from Tokyo and London.
How it makes money
Bugworks does not sell a product yet — BWC0977 is still in Phase 1 — so its “revenue” today is not commercial sales but a mix of grant income, milestone and service payments recognised against its research programmes, the kind of accounting common to a pre-revenue biotech that runs on non-dilutive funding as much as equity.
- Grant and programme income: non-dilutive funding from bodies such as CARB-X is drawn down against research milestones, which is the most plausible source of the operating revenue Bugworks Research India Private Limited reports in its RoC filings, since the company has no marketed drug.
- Partner-funded development: GARDP’s 2024 and 2025 agreements fund specific slices of clinical work (the IV and oral formulations of BWC0977) in exchange for future distribution rights in low- and middle-income countries — the company gets its trial paid for; GARDP gets guaranteed access to the drug if it works.
- Where the eventual margin would sit: if BWC0977 is approved, the commercial upside sits in the high-income markets Bugworks keeps for itself (US, EU, Japan), not the 146 countries assigned to GARDP — a structure that trades away most of the world’s unit volume in return for someone else funding the expensive part of getting there.
- The part people get wrong: assuming a “biotech with $42 million raised” is burning cash purely on a bet with no near-term inflows. In practice, a meaningful share of that capital is grant and partnership money tied to specific deliverables, not open-ended venture risk capital — which is also why the company’s reported revenue (₹27.8 crore in FY23) sits well above what a purely pre-revenue startup would show.
The numbers
Bugworks Research India Private Limited’s audited numbers are not fully public; detailed RoC filings beyond a two-year comparison are held behind data-provider paywalls (Tofler), and the company has not disclosed FY24 or FY25 figures in the press to date. What is verifiable is a two-year revenue trend and the direction of profitability:
| Metric (₹ crore) | FY22 | FY23 |
| Revenue | 19.9 | 27.8 |
| Revenue growth (YoY) | — | 39.8% |
| Net result | Not disclosed | Loss (negative net margin, exact figure undisclosed) |
Source: Tofler’s Registrar of Companies-filing-based summary for Bugworks Research India Private Limited (CIN U73100KA2014PTC073409), accessed September 2026. EBITDA is reported by Tofler to have risen 58.5% year-on-year in FY23 and book net worth by 33.4%, consistent with fresh equity (the $18 million Series B1 closed in February 2022) landing on the balance sheet during that window, though Tofler does not publish the absolute figures behind those percentages without a paid subscription.
Where the money comes from
- By geography of capital, not revenue: the overwhelming majority of Bugworks’ funders are outside India — UTEC and Global Brain from Japan, Lightrock India (an India-dedicated fund backed by international LPs), and Acquipharma Holdings from South Africa. Anandkumar himself put it starkly to Forbes India in June 2022: “For every hundred dollars I’ve raised for this company, hardly $2 has come from India.”
- By programme: the antibacterial programme (BWC0977, IV and oral) is by far the more advanced and better-funded of the two platforms, having reached Phase 1 in humans; the immuno-oncology programme, built around an adenosine-pathway asset developed with Cytecare Cancer Hospitals since a partnership announced 19 September 2022, remains pre-clinical.
- The surprise: a company selling nothing commercially yet reports ₹27.8 crore of FY23 revenue (Tofler) — a reminder that for a grant- and partnership-heavy biotech, “revenue” is a research-funding line item, not a proxy for a product in the market.
The risks
- Single-asset concentration risk: almost all of Bugworks’ clinical progress rides on one molecule, BWC0977. The mechanism is visible in its own trial data — a cardiac-safety sub-study had to be added by June 2022 (GARDP), and Forbes India (March 2025) later reported a blood-clotting event at the infusion site in two healthy volunteers during the IV arm. Either finding, unresolved, could stall the company’s most advanced programme and, with it, most of its near-term prospects.
- A structurally weak commercial market for antibiotics: new antibiotics are used sparingly and priced to be rationed, which is why large pharmaceutical companies have exited the category — the same dynamic that shut down AstraZeneca’s Avishkar unit in 2014 and created Bugworks in the first place. The company has mitigated this by giving away distribution rights in 146 lower-income countries to GARDP in exchange for funding, but that structure means most of the world’s disease burden generates no direct revenue for Bugworks even if the drug succeeds.
- Thin, foreign-heavy capital base: with “hardly $2” of every $100 raised coming from India, per Anandkumar’s own account to Forbes India, the company’s runway depends on continued conviction from a small set of Japanese, European and South African investors and non-profits (CARB-X, GARDP) rather than a deep domestic biotech capital market — a concentration risk if any one of those relationships cools.
The takeaway
Bugworks Research’s story is not really about a drug. It is about what a founder does when the market for the thing worth building has already failed once, visibly, in front of them. Anandkumar and his co-founders did not set out to fix the broken economics of antibiotic development; they built a company by giving up the parts of the story a normal biotech would fight to keep — global distribution rights, a purely equity-funded balance sheet, the assumption that revenue must come from selling the drug itself — in exchange for the one thing that couldn’t be replaced: enough runway to keep the molecule alive through the ugly parts of a clinical trial. The lesson travels well past antibiotics. When the commercial market for your product is structurally broken, the founders who survive are usually the ones who redesign what “making money” means for their business, rather than the ones who wait for the market to fix itself.
Frequently asked questions
What does Bugworks Research do?
Bugworks Research is a Bengaluru-founded biotech that designs antibiotics against drug-resistant “superbug” infections, led by its candidate BWC0977, alongside an early-stage immuno-oncology programme for solid tumours developed with Cytecare Cancer Hospitals.
Who founded Bugworks Research and when?
It was founded in 2014 by Anand Anandkumar, Santanu Datta, V. Balasubramanian and Shahul Hameed, four scientists who had worked together at AstraZeneca’s Bengaluru infectious-disease research centre, Avishkar, before AstraZeneca shut that unit down.
How much funding has Bugworks Research raised?
Bugworks has raised more than $42.9 million in equity across a Series A ($9 million, 2018), Series B ($7.5 million, 2020) and Series B1 ($18 million, 2022), per Tracxn and Inc42 company profiles, plus non-dilutive grant funding of roughly $8 million to date, primarily from CARB-X (Forbes India, March 2025).
What happened in the BWC0977 Phase 1 trial?
Bugworks started the first-in-human Phase 1 study of BWC0977 in Adelaide, Australia, on 8 November 2021. The programme later required a dedicated cardiac-safety sub-study, funded by GARDP from June 2022, and Forbes India reported in March 2025 that blood clotting was observed at the infusion site in two healthy volunteers during the intravenous arm of the trial.
Is Bugworks Research profitable or listed on a stock exchange?
No. Bugworks Research is a private, unlisted company. Its India entity reported ₹27.8 crore in revenue for FY23 (year ended 31 March 2023) with a net loss, per Tofler’s RoC-filing-based data, and it has not disclosed FY24 or FY25 results publicly.
Sources
Figures are as of September 2026. Currency converted at $1 ≈ ₹96.0 as of 18 September 2026 (Trading Economics).
- PR Newswire, “Bugworks Research Inc Raises $9M Series-A Financing to Develop Novel Antibiotics to Fight Superbugs,” August 2018
- Inc42, “Bugworks Raises $7.5 Mn Series B To Kill Drug-Resistant Bacteria,” April 2020
- Inc42, “Biotech Startup Bugworks Raises $18 Mn From Lightrock, Others To Fight Off Drug-Resistant Bacteria,” February 2022
- Tracxn, Bugworks Research company profile, accessed September 2026
- Inc42, Bugworks company financial profile, accessed September 2026
- Tofler, Bugworks Research India Private Limited company and financials pages (RoC-filing-based), accessed September 2026
- Forbes India, “Bugworks: How an Indian Avenger is building a life-saving biopharma weapon,” June 2022
- Forbes India, “FILA 2025 Emerging Innovator: How Bugworks is innovating a novel class of antibiotics, cancer drugs,” March 2025
- GARDP, “GARDP supports Bugworks in assessing safety of new antibiotic compound,” June 2022
- GARDP, BWC0977 portfolio page, accessed September 2026
- CIDRAP, “GARDP, Bugworks to collaborate on development of new broad-spectrum antibiotic,” June 2024
- CARB-X, portfolio listing for Bugworks Research, accessed September 2026
- Bugworks Research, official “News” page, accessed September 2026
- Bugworks Research, official “Our Team” page, accessed September 2026
Found an error? Write to us and we’ll correct it in the open, dated, on the piece.